In 2016, revenue within the industry hit an all-time high of more than $467 million and is projected to reach up to $769.4 million by 2022, at a compound annual growth rate of 10.5%.1 Across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK and Japan, the vaccine market has been predicted to increase from $3.1 billion last year to $4.3 billion in 2025.2
Global vaccine manufacturing is even brighter. A $6 billion market in 2000 has skyrocketed to $33 billion in 2014 … with no signs of slowing.3
Consistent growth, attributed to both the seasonality of vaccines and the need created by an unpredictable epidemic, has created a highly competitive market wherein 80% of global vaccine sales stem from five companies. This is compounded by the fact that a limited number of companies enter the market because of the strict international standards of quality control established by the World Health Organization (WHO), in which a lack of competition creates a pendulum swinging between supply and demand.4
This is especially true in the global influenza vaccine market, in which the scalability to reach pandemic levels of infection prevention remains questionable, as seen with H1N1 for influenza in 2009.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.
